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This supplement represents the proceedings of a
symposium, which took place during the ECC-
MID 2007, entitled ‘Selecting Empiric Antibiotic
Therapy in an Era of Multi-Drug Resistance—Is
the Cupboard Really Bare?’ In one form or
another, that question has been asked many times
before. Not unexpectedly, in reading the four
contributions, one will not ﬁnd an unambiguous
answer, and the authors address the question
from quite different angles. However, with no
reading between the lines required, so much will
be clear: the cupboard is not completely full.
G. M. Rossolini and E. Mantengoli highlight the
resistance situation in Europe, which empirical
therapy must take into account, by reviewing
currently available data and trends, particularly
with respect to the major culprits, methicillin-
resistant Staphylococcus aureus, extended-spec-
trum b-lactamase-producing Enterobacteriaceae,
and multidrug-resistant Gram-negative non-fer-
menters.
M. Caı´nzos discusses available treatment
guidelines as focused on skin and soft tissue
infections and complicated intra-abdominal infec-
tions, also with emphasis on the problems raised
by multidrug-resistant pathogens and their in-
creased prevalence.
Four new compounds, derived from the ceph-
alosporin, carbapenem, dihydrofolate reductase
inhibitor and tetracycline classes of antibiotics,
with greater intrinsic activity, or the capacity to
evade resistance mechanisms, or both, are the
subject of the two other articles.
All of the new compounds—will they be ﬁt to
ﬁll a space in the cupboard?—have been evalu-
ated in phase 3 studies.
Scrutinizing the ‘antimicrobial horizon’, to use
his term, G.L. French gives a comprehensive
overview of the spectrum of activity, pharmaco-
kinetic–pharmacodynamic and clinical trial data
available for ceftobiprole, doripenem, and icla-
prim.
While giving a similarly comprehensive over-
view of tigecycline, L.R. Peterson uses the occa-
sion to discuss the concept of monotherapy as a
possible means of reducing drug pressure that, as
he puts it, ‘might lead to a slowing of resistance
development’.
Taken together, the contributions to this issue
present selected, but nonetheless ample, data
concerning antimicrobial resistance and antimi-
crobial therapy—and material for reﬂection.
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